stockrowMadrigal Pharmaceuticals, Inc. (MDGL) vs Protagonist Therapeutics, Inc. (PTGX)
- Madrigal Pharmaceuticals, Inc. MDGL 433.44 +0.72%
- Protagonist Therapeutics, Inc. PTGX 140.29 −3.15%
Madrigal Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. are both Biotechnology companies. Madrigal Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. are of similar size ($9.9B and $9.4B). Madrigal Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Protagonist Therapeutics, Inc. trades at 115×. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against 34.8%. Protagonist Therapeutics, Inc. has the higher net margin (29.4% vs −25.3%) and the higher return on invested capital (61.8% vs −787.3%). Across the 17 metrics below, Protagonist Therapeutics, Inc. leads on 12 and Madrigal Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | MDGL | PTGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.48% | 100.00% | 69.20% |
| Operating margin | (25.13%) | 20.69% | 0.00% |
| Net margin | (25.32%) | 29.40% | 0.00% |
| Free cash flow margin | (16.07%) | 46.31% | 0.00% |
| Return on equity | (53.31%) | 10.98% | (53.10%) |
| Return on assets | (28.77%) | 10.34% | (46.06%) |
| Return on invested capital | (787.33%) | 61.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack